Final MRI Results at 6 Months from a Phase 2 Multicenter Study of Ublituximab, A Novel Glyocoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS), Demonstrates Complete Elimination of Gd-Enhancing Lesions By admin / 04/24/2018
6 Month Results of a Phase 2a Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Relapsing Multiple Sclerosis By admin / 02/01/2018
Placebo controlled, phase 2a multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS): 6 months analysis of B cell subsets By admin / 10/27/2017
Patient characteristics, safety, and preliminary results of a placebo controlled, phase 2a multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis By admin / 10/26/2017
Preliminary results of phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS) demonstrates rapid Gd-enhancing lesions decrease By admin / 10/26/2017
Rapid and Robust B Cell Depletion in Preliminary Results of Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing forms of Multiple Sclerosis (RMS) By admin / 06/24/2017
Rapid and Robust B Cell Depletion in Preliminary Results of a Phase 2 Study of Ublituximab, Novel Glycoengineered Anti-CD20 Mab, RMS Patients By admin / 05/26/2017
Preliminary results of Phase 2 Multicenter Study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of Multiple Sclerosis (RMS) demonstrates rapid and robust B cell depletion By admin / 04/28/2017
Open Label Safety Study of Ublituximab for the Treatment of Acute Neuromyelitis Optica Relapses By admin / 09/14/2016
